Lantern Pharma (LTRN) Tops Q4 EPS by 1c

Lantern Pharma (NASDAQ: LTRN) reported Q4 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c